In a nationally representative sample of office-based psychiatrists, the percentage of patient visits involving at least 30 minutes of psychotherapy dropped from 44% in 1996-1997 to 29% in 2004-2005.
Most authorities in the world of borderline personality disorder (BPD) say that psychotherapy is the mainstay of treatment and that medications should only be used adjunctively to treat symptoms as they arise. Nevertheless, medications are used relatively frequently for this disorder.
Cephalon’s selective GABA reuptake inhibitor, the antiepileptic drug tiagabine (Gabitril), was assessed for the treatment of generalized anxiety disorder in adults in three large 10-week placebo-controlled studies.
The FDA issued a Not Approvable letter regarding Vanda Pharmaceutical’s antipsychotic medication iloperidone (Fanapta). The agency based its decision on iloperidone’s question able efficacy results versus risperidone.
Based on data from eight randomized double-blind, placebo-controlled trials, researchers found that 79% of patients who responded to placebo in the initial phase of the trial maintained their response while continuing to take placebo during the continuation phase of the trial.
An intensive two-year-long early intervention for first episode psychosis showed early promise relative to standard care, yielding superior improvement in both positive and negative symptoms, as well as lower rates of substance abuse and lower antipsychotic medication doses.
Much of what is confusing and controversial in the treatment of bipolar disorder revolves around the role of antidepressants. Are they dangerous or safe? Are they effective or ineffective? Does it matter whether the patient has Bipolar I or II?